An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: The GC4 study

Cancer

Volumn 106, Issue 9, 2006, Pages 1908-1916

  Ajani, Jaffer A ^a   Hecht, J Randolph ^b   Ho, Linus ^a   Baker, Jackie ^e   Oortgiesen, Marga ^c   Eduljee, Arnavaz ^e   Michaeli, Dov ^d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CATO RESEARCH LTD   (United States)

^d Aphton Corporation   (United States)

^e Mail Stop 426 ^*

Author keywords

5 fluorouracil; Antigastrin antibodies; Cisplatin; Gastric cancer; Karnofsky performance status; Overall survival; Time to tumor progression; Vaccination

Indexed keywords

CISPLATIN; DIPHTHERIA VACCINE; FLUOROURACIL; G17DT VACCINE; GASTRIN; GASTRIN 17; GASTRIN ANTAGONIST; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTIBODY TITER; ARTICLE; BLOOD DISEASE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DEHYDRATION; DIARRHEA; DRUG SAFETY; ESOPHAGEAL ADENOCARCINOMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; IMMUNE RESPONSE; INFECTION; INFESTATION; INJECTION SITE ABSCESS; INJECTION SITE REACTION; LEUKOPENIA; LYMPHATIC SYSTEM DISEASE; MALE; METABOLIC DISORDER; MOUTH PAIN; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; NUTRITIONAL DISORDER; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SIDE EFFECT; STOMACH ADENOCARCINOMA; STOMATITIS; SYNCOPE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VASCULAR DISEASE; WEAKNESS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; CISPLATIN; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; GASTRINS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; STOMACH NEOPLASMS; VACCINATION;

EID: 33646358252     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21814     Document Type: Article

References (28)

1. Aphton Corporation. Aphton Investigator Brochure: Human G17DT Immunogen. San Francisco: Aphton Corporation, 2003. Available at URL: http://www.aphton.com [accessed June 1, 2005].
2. Kobori O, Vuillor MT, Martin F. Growth response of rat stomach cancer cells to gatro-entero-pancreatic hormones. Int J Cancer. 1982;30:65-67.
3. Ochai A, Yasui W, Tahara E. Growth-promoting effects of gastrin on human gastric carcinoma cell line TMK-1. Jpn J Cancer Res. 1985;76:1064-1067.
4. Watson S, Durrant L, Morris D. Gastrin: growth enhancing effects on human gastric and colonic tumour cells. Br J Cancer. 1989;59:554-558.
5. Rehfeld JF, Van Solinge WW. The tumor biology of gastrin and cholecystokinin. Adv Cancer Res. 1991;63:295-347.
6. McWilliams DF, Watson SA, Crosbee DM, et al. Coexpression of gastrin and gastrin receptor (CCK-B and delta CCK-B) in gastrointestinal tumour cell lines. Gut. 1998;42:795-798.
7. Aly A, Shulkes A, Baldwin GS. Gastrins, cholecystokinins and gastrointestinal cancer. Biochim Biophys Acta. 2004;1704:1-10.
8. Iwata N, Murayama T, Matsumori Y, et al. Autocrine loop through cholecystokinin-B/gastrin receptors involved in growth of human leukemia cells. Blood. 1996;88:2683-26899.
9. Schaer JC, Reubi JC. High gastrin and cholecystokinin (CCK) gene expression in human neuronal, renal, and myogenic stem cell tumors: comparison with CCK-A and CCK-B receptor contents. J Clin Endocr Metab. 1999;84:223-239.
10. Lefranc F, Mijatovic T, Mathieu V, et al. Characterization of gastrin-induced proangiogenic effects in vivo in orthotopic U373 experimental human glioblastomas and in vitro in human umbilical vein endothelial cells. Clin Cancer Res. 2004;10:8250-8265.
11. Konturek PC, Nikiforuk A, Kania J, Raithel M, Hahn EG, Muhldorfer S. Activation of NFkappaB represents the central event in the neoplastic progression associated with Barrett's esophagus: a possible link to the inflammation and overexpression of COX-2, PPARgamma and growth factors. Dig Dis Sci. 2004;49:1075-1083.
12. Wu H, Rao GN, Dai B, Singh P. Autocrine gastrins in colon cancer cells up-regulate cytochrome C oxidase Vb and down-regulate efflux of cytochrome C and activation of caspase-3. J Biol Chem. 2000;275:32491-32498.
13. Todisco A, Ramamoorthy S, Witham T, et al. Molecular mechanisms for the antiapoptotic action of gastrin. Am J Physiol Gastrointest Liver Physiol. 2001;280:298-307.
14. Ogasa M, Miyazaki Y, Hiraoka S, et al. Gastrin activates nuclear factor kappaB (NFkappaB) through a protein kinase C dependent pathway involving NFkappaB inducing kinase, inhibitor kappaB (IkappaB) kinase, and tumour necrosis factor receptor associated factor 6 (TRAF6) in MKN-28 cells transfected with gastrin receptor. Gut. 2003;52:813-819.
15. Wang TC, Dangler CA, Chen D, et al. Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer. Gastroenterology. 2000;118:36-47.
16. Watson SA, Michaeli D, Justin T. Pre-clinical evaluation of the gastrimmune immunogen alone and in combination with 5-FU/leucovorin in a rat colorectal cancer model. Int J Cancer. 1998;75:873-877.
17. Watson S, Michaeli D, Grimes S. Anti-gastrin antibodies raised by gastrimmune inhibit growth of the human colorectal tumor AP5. Int J Cancer. 1995;61:233-240.
18. Watson S, Michaeli D, Morris T. Gastrimmune reduces lung metastases in a human colorectal model [abstract]. Gut. 1995;37:A37.
19. Watson SA, Michaeli D, Grimes S, et al. Gastrimmune raises antibodies that neutralize amidated and glycine-extended gastrin-17 and inhibit the growth of colon cancer. Cancer Res. 1996;56:880-885.
20. Watson SA, Morris T, Robinson GK, et al. Therapeutic effects of anti-gastrin antibodies raised by gastrimmune on a human gastric cancer ascites line MGLVA1 [abstract]. Proc AACR. 1994;436:253.
21. Ajani JA, Van Cutsem J, Moiseyenko V, et al. Docetaxel (D), cisplatin, 5-fluorouracil compare to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naive patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): interim results of a randomized Phase III trial (V325) [abstract]. Proc Am Soc Clin Oncol. 2003;22:249.
22. Vanhoefer U, Rougier P, Wilke H, et al. Final results of a randomized Phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer. J Clin Oncol. 2000;18:2648-2657.
23. Rougier P, Ducrex M, Mahjoubi M, et al. Efficacy of combined 5-flourouracil and cisplatinum in advanced gastric carcinomas: a Phase II trial with prognostic factor analysis. Eur J Cancer. 1994;30A:1263-1269.
24. Kim NK, Park YS, Heo DS, et al. A Phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer. 1993;71:3813-3818.
25. Kyoto Research Group for Chemotherapy of Gastric Cancer (KRGCGC). A randomized, comparative study of combination chemotherapies in advanced gastric cancer: 5-fluorouracil and cisplatin (FP) versus 5-fluorouracil, cisplatin, and 4′-epirubicin (FPEPIR). Anticancer Res. 1992;12(6B):1983-1988.
26. Lacave AJ, Baron FJ, Anton LM, et al. Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: a Phase II trial. Ann Oncol. 1991;2:751-754.
27. Ohtsu A, Shimada Y, Shirao K, et al. Randomized Phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group study (JCOG9205). J Clin Oncol. 2003;21:54-59.
28. Williamson SK, Tangen CM, Maddox AM, et al. Phase II evaluation of low-dose continuous 5-fluorouracil and weekly cisplatin in advanced adenocarcinoma of the stomach. A Southwest Oncology Group study. Am J Clin Oncol. 1995;18:484-487.